PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Omaveloxolone→

Omaveloxolone PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1474034-05-3
Molecular formula
C33H44F2N2O3
Molecular weight
554.7 g/mol
Drug class
Nuclear factor erythroid 2-related factor 2 (Nrf2) pathway activatorantioxidant-response modulator
Mechanism of action
Activates the Nrf2 pathway and may suppress pro-inflammatory NF-kB signalling. The precise mechanism by which omaveloxolone improves neurological function in Friedreich ataxia is not fully established; its action is associated with regulation of cellular antioxidant and mitochondrial stress responses.
Indications / reported uses
  • Treatment of Friedreich ataxia in adults and adolescents aged 16 years and older under the US SKYCLARYS indication; clinical benefit should be interpreted within the approved label and long-term monitoring requirements

Sources: US DailyMed — SKYCLARYS (omaveloxolone) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Omaveloxolone PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Omaveloxolone Permitted Daily Exposure (PDE) report (the Omaveloxolone PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Omaveloxolone Occupational Exposure Limit (OEL) report (the Omaveloxolone OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.